Pulmonary arterial hypertension

This study tests whether implanted monitors can quickly show if a new PAH drug is working. About 40 adults with stable PAH will try two different approved drug plans while their heart and lung function are tracked. The goal is to see if this approach can help doctors choose the b…

This study tests whether adding selexipag to standard treatment can delay disease worsening in children aged 2 to 18 with pulmonary arterial hypertension (PAH). About 138 children will receive either selexipag or a placebo, plus their usual medications. The main goal is to see if…

This study looks at the long-term safety of an inhaled drug called GB002 for people with pulmonary arterial hypertension (PAH), a serious lung condition. It includes 74 patients who already completed a previous GB002 study. Researchers will track side effects and measure how far …

This study is testing the long-term safety and tolerability of an inhaled treprostinil powder (TPIP) in people with pulmonary arterial hypertension (PAH). About 91 participants who completed earlier TPIP studies will receive the drug for up to several years. Researchers will moni…

This study is testing the safety and right dose of a drug called selexipag in children aged 2 to 17 with pulmonary arterial hypertension (PAH), a serious condition where blood pressure in the lungs is too high. The goal is to find a dose that works like the adult version. The stu…

This phase 3 trial compares two doses of macitentan (75 mg vs 10 mg) in about 935 adults with pulmonary arterial hypertension. The goal is to see if the higher dose can delay serious events like hospitalization or death. Participants will be followed for several years.

This study tests a drug called riociguat in children aged 6 to 18 who have pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe and move. The goal is to see if the drug is safe and how the body processes it at differen…

This early study tests a small, permanent device called the V-Wave Interatrial Shunt in 9 people with severe pulmonary arterial hypertension (PAH). The device is placed in the heart during a minimally invasive procedure to create a small opening between the upper chambers, which …

This early-stage study by Pfizer tests a new drug called PF-07868489. First, it will be given to healthy volunteers to check safety and how the body processes it. Then, people with pulmonary arterial hypertension (PAH) will receive repeated doses over 24 weeks to see if it helps …

This study tests a new drug, Oxacom®, in 200 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. The drug is given in different doses to see if it can lower pressure in the lung's blood vessels better than a placebo. The goal…

This study is a patient registry that follows 300 adults with pulmonary arterial hypertension (PAH) who are starting or recently started Orenitram. Researchers will track how well patients tolerate the drug and how it affects their daily function and symptoms over 78 weeks. The g…

This study tests a new inhaled drug called L606 (liposomal treprostinil) in 28 adults with pulmonary arterial hypertension or PH-ILD. The goal is to see if it is safe and tolerable when taken twice daily, both short-term and over a year. Participants either switch from another in…

This study looks at the long-term safety of the drug ralinepag in people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. About 1,000 adults who were in earlier ralinepag studies can join. The goal is to see if the drug remains s…

This study tests an implanted catheter and pump system that delivers Remodulin, a drug for pulmonary arterial hypertension (PAH), directly into the bloodstream. The goal is to see if this device is safe for long-term use. The trial includes 64 patients who already use the system.…

This study tests whether quickly starting and increasing a medication called treprostinil can lower blood pressure in the lungs and improve the heart's pumping ability in people with pulmonary arterial hypertension (PAH). The trial involves 52 adults with PAH and will measure cha…

This study looks at the long-term safety of a medicine called sotatercept for people with pulmonary arterial hypertension (PAH). Participants from an earlier study can join and receive weight-based doses every 3 weeks. The main goal is to see if the medicine is safe and well-tole…

This study tests whether a 12-week program of exercise and diet counseling can improve insulin sensitivity and heart function in people with pulmonary arterial hypertension (PAH). The 34 participants have stable PAH and are already on standard medications. The goal is to see if l…

This trial is developing an artificial intelligence system that reads electrocardiograms (ECGs) to detect congenital heart disease in children. Researchers are collecting ECG data from thousands of children, including those with common and rare heart defects, to train a deep-lear…

This study tests whether a home rehabilitation program using daily text or email messages with simple exercises can reduce the number of heartbeats needed during a 6-minute walk in people with pulmonary arterial hypertension (PAH). Researchers will enroll 55 adults with PAH and c…

This study tests whether whole-body aerobic training (like brisk walking) or isolated leg training (with weights) better improves symptoms and quality of life in people with pulmonary arterial hypertension (PAH). About 45 participants with PAH will be assigned to one of the two e…

This study tests whether exercise delivered through immersive virtual reality can improve physical performance, muscle strength, fatigue, and quality of life in 32 adults with idiopathic pulmonary arterial hypertension. Participants will do virtual reality exercises and be measur…

This study investigates whether a drug called XBD173, which targets a protein (TSPO) on blood vessel lining cells, can help understand how these cells contribute to pulmonary artery hypertension (PAH). PAH is a rare condition where narrowed lung blood vessels strain the heart. Si…

This study was designed to see if a test using acetylcholine could predict whether people with congenital heart disease and high blood pressure in the lungs would develop worsening high blood pressure after surgery to close a heart shunt. The test would have measured how well the…

This study looks at whether people with pulmonary arterial hypertension (PAH) have changes in thinking skills like memory and attention. Researchers will compare 30 PAH patients to healthy volunteers using computer-based tests. The goal is to better understand how PAH might affec…

This study was designed to see if a non-invasive finger cuff device could accurately measure how well the heart pumps blood in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). The goal was to replace the usual invasive ri…

This study looks at how different types of fats in the blood (like cholesterol) are linked to complications in adults with sickle cell disease. Researchers will follow 116 participants from the French Caribbean islands to track their fat levels over time and during acute events l…

This study is collecting blood samples from 550 adults with different types of pulmonary hypertension to measure two proteins, Activin-A and FSTL3. Researchers want to see if these proteins can predict who will need a lung transplant or die within two years. The goal is to find a…

This study looks at nearly 1,200 people with or at risk for pulmonary hypertension (high blood pressure in the lungs). Researchers use many advanced tests to find new ways to classify the disease and identify biomarkers. The goal is to better understand the disease and improve fu…